Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxm1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 8	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 13	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 14	DEC 18	CA/CAplus patent kind codes updated
NEWS 15	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 17	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 19	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 22	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 23	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 24	JAN 29	PHAR reloaded with new search and display fields
NEWS 25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 26	FEB 13	CASREACT coverage to be extended
NEWS 27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 29	Feb 23	KOREAPAT enhanced with IPC 8 features and functionality

NEWS EXPRESS	NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 22:40:46 ON 23 FEB 2007

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 22:41:01 ON 23 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 FEB 2007 HIGHEST RN 922800-14-4
DICTIONARY FILE UPDATES: 22 FEB 2007 HIGHEST RN 922800-14-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10505386.str





chain nodes :
17
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
8-17 9-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-17 9-10 10-11 10-15 11-12
12-13 13-14 14-15
isolated ring systems :
containing 10 :

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sam
SAMPLE SEARCH INITIATED 22:41:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       113 TO ITERATE

100.0% PROCESSED       113 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:          1623 TO     2897
PROJECTED ANSWERS:                0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 22:41:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      2148 TO ITERATE

100.0% PROCESSED      2148 ITERATIONS                                 31 ANSWERS
SEARCH TIME: 00.00.01

L3            31 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     172.10     172.31

FILE 'CAPLUS' ENTERED AT 22:41:34 ON 23 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 23 Feb 2007 VOL 146 ISS 10
FILE LAST UPDATED: 22 Feb 2007 (20070222/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 3 L3

=> d l4 ibib hitstr abs 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:386432 CAPLUS
DOCUMENT NUMBER: 144:425692
TITLE: Methods using TGF-β type I receptor inhibitors and Alk4 inhibitors for treating vascular injuries
INVENTOR(S): Ling, Leona E.; Fu, Kai; Gill, Alan; Gotwals, Philip J.
PATENT ASSIGNEE(S): Biogen Idec Ma Inc., USA
SOURCE: PCT Int. Appl., 228 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044509	A2	20060427	WO 2005-US36770	20051013
WO 2006044509	A3	20060817		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-619116P P 20041015
OTHER SOURCE(S): MARPAT 144:425692
IT 672932-52-4 672932-53-5 672932-56-8
RL: DEV (Device component use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TGF-β type I receptor inhibitors and Alk4 inhibitors for treating vascular injuries)
RN 672932-52-4 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(6-chloro-2-pyridinyl)pyrazolo[1,5-c]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 672932-53-5 CAPLUS
CN Pyrazolo[1,5-c]pyrimidine, 2-(6-methyl-2-pyridinyl)-3-[2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 672932-56-8 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-c]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



AB The invention discloses the use of TGF-β type I receptor inhibitors and Alk4 inhibitors and implantable devices including these compds. in treating, preventing, or reducing intimal thickening, vascular remodeling, restenosis (e.g., coronary, peripheral, carotid restenosis), vascular diseases, (e.g., organ transplant-related, cardiac, lung and renal), and hypertension (e.g., primary and secondary hypertension, systolic hypertension, pulmonary hypertension, and hypertension-induced vascular remodeling resulting in target organ damage).

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:220201 CAPLUS
DOCUMENT NUMBER: 140:270867
TITLE: Preparation of pyrazolopyridines as antagonists of Alk 5 and/or Alk 4
INVENTOR(S): Lee, Wen-cherng; Carter, Mary Beth; Sun, Lihong; Lyne, Paul; Chuaqui, Claudio; Zheng, Zhongli; Singh, Juswinder; Boriack-Sjodin, Paula
PATENT ASSIGNEE(S): Biogen, Inc., USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004022054	A1	20040318	WO 2003-US27722		20030905
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2497970	A1	20040318	CA 2003-2497970		20030905
AU 2003268447	A1	20040329	AU 2003-268447		20030905
EP 1551398	A1	20050713	EP 2003-749412		20030905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003014053	A	20050719	BR 2003-14053		20030905
CN 1694698	A	20051109	CN 2003-824867		20030905
JP 2006502165	T	20060119	JP 2004-534571		20030905
NO 2005001503	A	20050321	NO 2005-1503		20050321
US 2006106033	A1	20060518	US 2005-526839		20051101
PRIORITY APPLN. INFO.:			US 2002-408811P	P	20020906
			WO 2003-US27722	W	20030905

OTHER SOURCE(S): MARPAT 140:270867

IT 672932-52-4P, [4-[2-(6-Chloropyridin-2-yl)pyrazolo[1,5-c]pyrimidin-3-yl]pyrimidin-2-yl]amine 672932-53-5P, 2-(6-Methylpyridin-2-yl)-3-(2-morpholin-4-ylpyrimidin-4-yl)pyrazolo[1,5-c]pyrimidine 672932-56-8P, [4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-c]pyrimidin-3-yl]pyrimidin-2-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyridines as antagonists of Alk 5 and/or Alk 4 for treating fibrotic disorders or diseases or disorders mediated by an overexpression of TGFβ)

RN 672932-52-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-chloro-2-pyridinyl)pyrazolo[1,5-c]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 672932-53-5 CAPLUS

CN Pyrazolo[1,5-c]pyrimidine, 2-(6-methyl-2-pyridinyl)-3-[2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 672932-56-8 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-c]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



GI



I

AB The title compds. [I; wherein each of X1-X4 is independently CRx or N; provided that only two of X1-X4 can be N simultaneously; each of Y1 and Y2 is independently CRy or N; provided that at least one of Y1 and Y2 must be N; R1 = alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, cyano, guanidino, amidino, carboxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, alkylsulfonylamino, alkoxycarbonyl, alkylcarbonyloxy, urea, thiourea, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfanyl, heterocycloalkyl, heterocycloalkyloxy, etc.; R2 = alkyl, alkenyl, alkynyl, acyl, halo, hydroxy, NH2, NH(alkyl), N(alkyl)2, NH(cycloalkyl), N(alkyl)(cycloalkyl), NH(heterocycloalkyl), NH(heteroaryl), NH-alkylheterocycloalkyl, NH-alkylheteroaryl, NH(aralkyl), cycloalkyl, (cycloalkyl)alkyl, aryl, aralkyl, aroyl, heterocycloalkyl, (heterocycloalkyl)alkyl, etc.; m = an integer of 0-4; n = an integer of 0-3; provided that when m >2, two adjacent R1 or R2 groups can join together to form a 4- to 8-membered optionally substituted cyclic moiety; Rx, Ry = H, alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, cyano, guanidino, amidino, carboxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, cycloalkylcarbonyl, (cycloalkyl)alkylcarbonyl, aroyl, aralkylcarbonyl, etc.] or pharmaceutically acceptable salts or N-oxides thereof. These compds. possess unexpectedly high affinity for transforming growth factor β (TGFβ) type I receptor (Alk 5) and/or activin receptor type I (Alk 4), and can be useful as antagonists thereof for preventing and/or

treating numerous diseases, including fibrotic disorders or diseases or disorders mediated by an overexpression of TGFβ. The fibrotic condition is selected from the group consisting of scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scarring, spinal cord injury, CNS scarring, acute lung injury, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury, glomerulonephritis, diabetic nephropathy, hypertension-induced nephropathy, hepatic or biliary fibrosis, liver cirrhosis, primary biliary cirrhosis, fatty liver disease, primary sclerosing cholangitis, restenosis, cardiac fibrosis, opthalmic scarring, fibrosclerosis, fibrotic cancers, fibroids, fibroma, fibroadenomas, fibrosarcomas, transplant arteriopathy, and keloid. The diseases or disorders mediated by an overexpression of TGFβ are selected from the group consisting of demyelination of neurons in multiple sclerosis, Alzheimer's disease, cerebral angiopathy, squamous cell carcinomas, multiple myeloma, melanoma, glioma, glioblastomas, leukemia, and carcinomas of the lung, breast, ovary, cervix, liver, biliary tract, gastrointestinal tract, pancreas, prostate, and head and neck.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:737760 CAPLUS
DOCUMENT NUMBER: 139:261327
TITLE: Preparation of pyrazolopyrimidines and pyrazolotriazines for treatment of herpes viral infections
INVENTOR(S): Gudmundsson, Kristjan; Johns, Brian A.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003076441	A1	20030918	WO 2003-US5704		20030224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003217712	A1	20030922	AU 2003-217712		20030224
EP 1485385	A1	20041215	EP 2003-713672		20030224
EP 1485385	B1	20050817			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
US 2005124616	A1	20050609	US 2003-505386		20030224
JP 2005525382	T	20050825	JP 2003-574658		20030224
AT 302203	T	20050915	AT 2003-713672		20030224
ES 2245772	T3	20060116	ES 2003-3713672		20030224
PRIORITY APPLN. INFO.:			US 2002-362298P	P	20020307
			WO 2003-US5704	W	20030224

OTHER SOURCE(S): MARPAT 139:261327
IT 601521-20-4P 601521-21-5P 601521-37-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazolopyrimidines and pyrazolotriazines for treatment of herpes viral infections)

RN 601521-20-4 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)pyrazolo[1,5-c]pyrimidin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 601521-21-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-7-(methylthio)pyrazolo[1,5-c]pyrimidin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 601521-37-3 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(methylthio)pyrazolo[1,5-c]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



IT 601521-18-0P 601521-19-1P 601521-22-6P
601521-23-7P 601521-24-8P 601521-25-9P
601521-29-3P 601521-30-6P 601521-31-7P
601521-32-8P 601521-33-9P 601521-34-0P
601521-35-1P 601521-36-2P 601521-38-4P
601521-39-5P 601521-40-8P 601521-41-9P
601521-42-0P 601521-43-1P 601521-44-2P
601521-45-3P 601521-46-4P 601521-47-5P
601521-48-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of pyrazolopyrimidines and pyrazolotriazines for treatment of herpes viral infections)

RN 601521-18-0 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 601521-19-1 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 601521-22-6 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, 2-(3-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 601521-23-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-c]pyrimidin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 601521-24-8 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, 2-(3-chlorophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 601521-25-9 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7(6H)-one, 2-(3-chlorophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 601521-29-3 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-N-cyclopentyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 601521-30-6 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 601521-31-7 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, 3-[2-(2-benzothiazolylamino)-4-pyrimidinyl]-N-cyclopentyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 601521-32-8 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[(4-methyl-2-thiazolyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 601521-33-9 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, 3-[2-(1H-benzimidazol-2-ylamino)-4-pyrimidinyl]-N-cyclopentyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 601521-34-0 CAPLUS

CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[[(4-fluorophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 601521-35-1 CAPLUS

CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[(2-phenylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 601521-36-2 CAPLUS

CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-3-[2-[(1,1-dimethylethyl)amino]-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 601521-38-4 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 601521-39-5 CAPLUS
CN Phenol, 4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-c]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



RN 601521-40-8 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 601521-41-9 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 601521-42-0 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, 2-(4-butoxyphenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 601521-43-1 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(2-methylpropoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 601521-44-2 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(2-methoxyethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 601521-45-3 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-propoxyphenyl)- (9CI) (CA INDEX NAME)



RN 601521-46-4 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(1,1-dimethylethyl)-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 601521-47-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-c]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 601521-48-6 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(1-piperidinyl)pyrazolo[1,5-c]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



GI



I



II

AB Title compds. I [A = (un)substituted heterocyclic; Y, Y1 = n, CH; R1, R5 = H, halogen, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, acyl, CO2H, CONH2, CSNH2, C(:NH)NH2, OH, NH2, SH, S(O)H, SO2H, CN, NO2, N3; R2 = halogen, (un)substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heterocyclic, OH, NH2, SO2NH2; R3, R4 = H, halogen, (un)substituted alkyl, alkenyl, cycloalkyl, aryl, heterocyclic, CO2H, OH, NH2, SO2NH2, acyl; p = 0-2] were prepared for use in the prophylaxis or treatment of a condition or disease associated with a herpes viral infection. Thus, the pyrazolopyrimidine II was prepared from 4-methyl-2-pyrimidinethiol in 8 steps and has IC50 for inhibition of HSV-1 of 0.72 μM.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.28	188.59
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

STN INTERNATIONAL LOGOFF AT 22:41:54 ON 23 FEB 2007